ReNerve

ASX Announcement

7 September 2026

ReNerve and RMIT awarded $499k grant for Nerve Regeneration Project

ReNerve Limited (ASX, "**ReNerve**" or "the **Company**"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("**PNI**") repair, in partnership with Royal Melbourne Institute of Technology ("**RMIT**") and Associate Professor Shadi Houshyar, have been awarded a $498,856 grant from the **Commonwealth of Australia through the Department of Education** for a project using patients own blood to accelerate nerve regeneration post prostate surgery.

The grant funding will be allocated between RMIT and ReNerve in accordance with the approved project budget. ReNerve's participation in the project is expected to provide access to collaborative research and potential future product development opportunities.

The technology holds potential beyond prostate surgery, with the partnership focused on development of a gel that is incorporated into a nerve cuff or wrap, and could be used with additional tissue products like ReNerve's nerve conduits and nerve guide matrix. The ReNerve's NervAlign products are designed not to just benefit patient recovery but also as platforms for delivery of cell therapies, enriched blood products and similar treatment products that focus on accelerated nerve repair and recovery.

"We are fortunate to be working with Associate Professor Houshyar on the next generation of nerve repair technologies and products. Being able to accelerate nerve regeneration would greatly benefit surgical outcomes as well as improving outcomes for patients," said Chief Scientific Officer Dr David Rhodes.

The partnership is underway and ReNerve will provide shareholders with ongoing updates as it progresses.

The project, 'Universal Platform for Tissue Regeneration and Healing: Addressing Nerve Injury', received grant funding from the **Department of Education** as part of Australia's Economic Accelerator (**AEA**) Ignite Round 2 projects under the AEA Launch Program.

Approximately 1 in 8 men are diagnosed with prostate cancer in their lifetime. Incidence rates are rising by 3% annually as of 2014–2021, reversing previous declines, with roughly 313,780 new cases estimated for 2025[1], with around 90,000 prostatectomies undertaken in the US each year.

The project is currently at the research and development stage and there can be no assurance that the technology will achieve its intended objectives, obtain regulatory approvals or result in a commercial product.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

[1] www.cancertherapyadvisor.com/factsheets/prostate-cancer-statistics

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product --** A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.[2]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[2] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)